TERT promoter mutation
Original Article TERT promoter mutation, telomere length, and TERT expression in gastric cancer
6
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
14
High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins
5
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
11
Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
13
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma
16
Germline TERT promoter mutations are rare in familial melanoma
6
Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma
10
Implications of TERT promoter mutations and telomerase activity for urothelial carcinogenesis
28
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation
10
MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours
8
Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma
9
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities
8
TERT p mutation ( P<0.0001) and simultaneously wild type of IDH and TERT p ( IDH wt TERT pwtP <0.0001) in midline than no-midline lobes. Logistic regression analysis indicated
18
BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients
10
Frequency of TERT promoter mutations in prostate cancer
16
The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer
10
(R) N {2 tert Butyl 2 [(R) tert butylsulfonamido]ethylidene} tert butanesulfonamide
11
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
30
Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer
9